Gauthier Kathryn M, Edwards Erik M, Falck John R, Reddy Dendi S, Campbell William B
Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA.
Hypertension. 2005 Apr;45(4):666-71. doi: 10.1161/01.HYP.0000153462.06604.5d. Epub 2005 Feb 7.
Bradykinin causes arterial relaxation and hyperpolarization, which is mediated by a transferable endothelium-derived hyperpolarizing factor (EDHF). In coronary arteries, epoxyeicosatrienoic acids (EETs) are involved in the EDHF response. However, the role of EETs as transferable mediators of EDHF-dependent relaxation remains poorly defined. Two small bovine coronary arteries were cannulated and perfused in tandem in the presence of the nitric oxide synthase inhibitor, nitro-L-arginine (30 micromol/L), and the cyclooxygenase inhibitor, indomethacin (10 micromol/L). Luminal perfusate from donor arteries with intact endothelium perfused endothelium-denuded detector arteries. Detector arteries were constricted with U46619 and diameters were monitored. Bradykinin (10 nmol/L) added to detector arteries did not induce dilation (5+/-2%), whereas bradykinin addition to donor arteries dilated detector arteries by 26.5+/-7% (P<0.05). These dilations were blocked by donor artery endothelium removal and detector artery treatment with the EET-selective antagonist, 14,15-epoxyeicosa-5(Z)-monoenoic acid (14,15-EEZE; 10 micromol/L, -5+/-6%) but not 14,15-EEZE treatment of donor arteries (20+/-5%). 14,15-EET (0.1 to 10 micromol/L) added to detector arteries induced maximal dilations of 82+/-5% that were inhibited 50% by detector artery treatment with 14,15-EEZE (32+/-12%) but not donor artery treatment with 14,15-EEZE. Liquid chromatography-electrospray ionization mass spectrometry analysis verified the presence of 14,15-EET in the perfusate from an endothelium-intact but not denuded artery. These results show that bradykinin stimulates donor artery 14,15-EET release that dilates detector arteries. 14,15-EEZE blocked the donor artery, endothelium-dependent, bradykinin-induced relaxations, and attenuated relaxations to 14,15-EET. These results suggest that EETs are transferable EDHFs in coronary arteries.
缓激肽可引起动脉舒张和超极化,这是由一种可转移的内皮源性超极化因子(EDHF)介导的。在冠状动脉中,环氧二十碳三烯酸(EETs)参与了EDHF反应。然而,EETs作为EDHF依赖性舒张的可转移介质的作用仍不清楚。将两根小牛冠状动脉插管并串联灌注,同时加入一氧化氮合酶抑制剂硝基-L-精氨酸(30 μmol/L)和环氧化酶抑制剂吲哚美辛(10 μmol/L)。来自具有完整内皮的供体动脉的腔内灌注液灌注内皮剥脱的检测动脉。检测动脉用U46619收缩,并监测其直径。向检测动脉中加入缓激肽(10 nmol/L)未引起舒张(5±2%),而向供体动脉中加入缓激肽可使检测动脉舒张26.5±7%(P<0.05)。这些舒张反应可被去除供体动脉内皮以及用EET选择性拮抗剂14,15-环氧二十碳-5(Z)-单烯酸(14,15-EEZE;10 μmol/L,-5±6%)处理检测动脉所阻断,但用14,15-EEZE处理供体动脉则不能阻断(20±5%)。向检测动脉中加入14,15-EET(0.1至10 μmol/L)可引起最大舒张82±5%,用14,15-EEZE处理检测动脉可抑制50%(32±12%),而用14,15-EEZE处理供体动脉则不能抑制。液相色谱-电喷雾电离质谱分析证实,完整内皮而非剥脱内皮的动脉灌注液中存在14,15-EET。这些结果表明,缓激肽刺激供体动脉释放14,15-EET,从而使检测动脉舒张。14,15-EEZE阻断了供体动脉依赖内皮的、缓激肽诱导的舒张反应,并减弱了对14,15-EET的舒张反应。这些结果提示,EETs是冠状动脉中可转移的EDHFs。